Search for: "PAR PHARMACEUTICALS COMPANIES, INC"
Results 21 - 40
of 90
Sorted by Relevance
|
Sort by Date
9 Sep 2011, 6:56 am
First, the AP (9/7, Johnson) reported Chicago pharmacist Bernard Lisitza is suing Par Pharmaceuticals Companies Inc., along with Australia’s Alphapharm PTY Ltd. and Canada’s Genpharm ULC, “in a whistleblower lawsuit of scheming to overcharge the government by tens of millions of dollars for medicines. [read post]
31 Jul 2020, 4:48 am
Complete Business Solutions Group Inc. d/b/a/ Par Funding et al. [read post]
30 Sep 2013, 8:12 am
District Court for the District of Delaware against Apotex Corp.; Hetero USA Inc.; Lupin Ltd.; Mylan Pharmaceuticals, Inc.; Par Pharmaceuticals, Inc.; Ranbaxy Laboratories Ltd.; and related companies and subsidiaries. [read post]
16 Sep 2021, 12:57 pm
Suffolk and Nassau Counties will each receive $13.85 million in combined settlements from Endo and its subsidiary Par Pharmaceutical, Inc. [read post]
19 Oct 2012, 6:13 pm
The majority of the assets in these 18 markets would be divested to Par Pharmaceutical, Inc. [read post]
18 Oct 2009, 5:42 pm
Judge Brown found that the patent in question, US Patent No. 5,565,473, was valid and enforceable, and [...]...FTC Sues Regarding AndroGel Patent Settlement The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition… [read post]
10 Oct 2011, 10:00 am
Teva, Ranbaxy Pharmaceuticals, Inc., Mylan Pharmaceutical Inc., and Barr Laboratories, Inc. - which Teva now owns - all have taken steps toward entering the market, and all are eligible to seek a 180-day marketing exclusivity provided under federal law. [read post]
FTC and California AG Join in Challenging Reverse Payment Settlements in the Pharmaceutical Industry
6 Mar 2009, 7:03 am
The complaint also names generic pharmaceutical companies Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories. [read post]
16 Oct 2006, 7:58 pm
Novartis sued Par Pharmaceuticals, the third and most recent company to file an ANDA for generic Lotrel. [read post]
17 Mar 2014, 11:03 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited (these three companies are, collectively, "Mylan"); Par Pharmaceutical Companies, Inc.; Par Pharmaceutical,… [read post]
13 Jun 2019, 11:24 am
Facts: This case (Par Pharmaceutical, Inc. et al v. [read post]
17 Jul 2014, 10:58 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco… [read post]
30 Jun 2014, 10:28 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco… [read post]
11 Apr 2013, 4:57 am
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of… [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
15 Jan 2013, 11:33 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
15 Sep 2011, 5:46 am
Attorney's office joined in the lawsuit, brought by Chicago pharmacist Bernard Lisitza in a 162-page complaint Defendants include Par Pharmaceuticals Companies Inc. of Woodcliff Lake, N.J., and two foreign generic drugmakers overcharged the Medicaid program by getting pharmacies to dispense different, more-expensive, dosage forms than what was prescribed. [read post]
22 Apr 2009, 6:14 am
Citigroup has been hit with a $30 million auction-rate securities lawsuit filed by Braintree Laboratories, Inc., a specialty pharmaceutical company, reported Christine Caufield in an April 17, 2009 article posted on Law360.com. [read post]
2 Dec 2009, 11:05 am
On December 2, 2009, the FTC announced an order settling charges that Watson Pharmaceuticals, Inc. [read post]
22 Jun 2010, 9:00 am
Matrixx Initiatives, Inc., 2005 U.S. [read post]
